Abstract
Chronic hepatitis B affects around 240 million people across the globe and is one of the main causes of end-stage liver disease and hepatocellular carcinoma. Existing treatment options consist of finite treatment with pegylated interferon alfa, which is infrequently used because of side-effects, or long-term treatment with a nucleo(s)tide analogue. Nucleos(t)ide analogues inhibit hepatitis B virus (HBV) DNA polymerase and result in profound suppression of HBV DNA production during continuous therapy. Long-term nucleos(t)ide analogue treatment is well tolerated, and has been shown to improve liver histology and to reduce the incidence of hepatocellular carcinoma. 1 Lampertico P Agarwal K Berg T et al. European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370-398 Summary Full Text Full Text PDF PubMed Scopus (2991) Google Scholar Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trialNo pattern of treatment-emergent adverse events was observed at ABI-H0731 doses up to 300 mg in individuals with chronic hepatitis B. ABI-H0731 was rapidly absorbed and exhibited a plasma half-life supportive of once-daily dosing. Dose-dependent decreases in serum HBV DNA and RNA concentrations are consistent with the proposed mechanism of action. Full-Text PDF
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call